Skip to main content
. Author manuscript; available in PMC: 2023 Nov 5.
Published in final edited form as: Eur J Pharm Sci. 2018 Jan 12;115:88–99. doi: 10.1016/j.ejps.2018.01.021

Figure 8.

Figure 8.

Pharmacokinetics of 264 in monkeys. 264 was administered by oral gavage to cynomolgus monkeys as described in Materials and Methods at doses of either 30 mg/kg (A) or 75 mg/kg (B) and the products were extracted and analyzed by RP-HPLC as shown in the legend to Fig. 5, using 190 as an internal standard. The concentrations of 264 (●), ω2-hydroxy-264 (△), and ω2-oxo-264 (▽) are shown. In the inset to panel B the plasma concentrations of 264 (30 (○) and 75 (●) mg/kg) at different time points are compared using a logarithmic scale. C: The percentage of 264 in the form of the R-enantiomer was determined for each of the time points shown in panel B (264, 75 mg/kg). The S and R enantiomers were separated by chiral HPLC as described in Materials and Methods.